Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,018.40
(
-2.10%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
100.67
(
1.92%
)
Bitcoin
68,904.06
(
-3.37%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 217438

Monday, 03/12/2018 4:14:40 PM

Monday, March 12, 2018 4:14:40 PM

Post# of 257295
ADXS—FDA clinical hold on phase-2 trial of AXAL+AZN’s Imfinzi in cervical cancer; other ADXS trials—including the AIM2CERV phase-3 trial of AXAL monotherapy in adjuvant cervical cancer—are unaffected:

http://ir.advaxis.com/press-release/advaxis-reports-fiscal-2018-first-quarter-financial-results-and-announces-clinical

The reason for the clinical hold is one unexplained death in the Imfinza trial.

The above PR also includes ADXS' FY1Q18 (1/31/18) financials.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today